-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
South San Francisco, California, USA--(Business Wire)--December 15, 2021--Twist Bioscience (NASDAQ: TWST) is a company that uses its silicon-based platform to provide high-quality synthetic DNA to help customers obtain A successful company, the company today announced the launch of a synthetic RNA positive control for the SARS-CoV-2 mutant strain Omi Keron (B.
Dr.
Dr.
To learn more about the products provided by Twist in the fight against COVID-19, including a full set of NGS test panels (panel) that track the emergence of new SARS-CoV-2 strains, please visit https:// research-tools
In March 2020, Twist first launched different SARS-CoV-2 synthetic RNA reference sequences, and is developing next-generation sequencing (NGS) and reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 detection.
The Twist synthetic control is designed based on a specific SARS-CoV-2 variant, covering the complete viral genome, and the sequence has been verified
Customers who purchase synthetic controls must comply with the biosafety inspection protocol led by Twist and applicable laws and regulations
About Twist Bioscience
Twist Bioscience is a leading and fast-growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to promote the industrialization of bioengineering
Legal statement regarding forward-looking statements
This press release contains forward-looking statements